IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more
IGM Biosciences Inc (IGMS) - Net Assets
Latest net assets as of June 2025: $100.93 Million USD
Based on the latest financial reports, IGM Biosciences Inc (IGMS) has net assets worth $100.93 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($106.99 Million) and total liabilities ($6.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $100.93 Million |
| % of Total Assets | 94.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -87.38% |
| 10-Year Change | N/A |
| Growth Volatility | 46.66 |
IGM Biosciences Inc - Net Assets Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IGM Biosciences Inc (2017–2024)
The table below shows the annual net assets of IGM Biosciences Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $48.17 Million | -76.30% |
| 2023-12-31 | $203.23 Million | -29.25% |
| 2022-12-31 | $287.26 Million | +17.29% |
| 2021-12-31 | $244.91 Million | -35.86% |
| 2020-12-31 | $381.81 Million | +58.94% |
| 2019-12-31 | $240.23 Million | +464.94% |
| 2018-12-31 | $-65.83 Million | -62.53% |
| 2017-12-31 | $-40.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IGM Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 97567600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $342.00K | 0.71% |
| Other Comprehensive Income | $159.00K | 0.33% |
| Other Components | $1.06 Billion | 2210.22% |
| Total Equity | $48.17 Million | 100.00% |
IGM Biosciences Inc Competitors by Market Cap
The table below lists competitors of IGM Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AQUILA ACQ.CORP. CL.A
F:T81
|
$76.58 Million |
|
Hanla IMS Co. Ltd
KQ:092460
|
$76.58 Million |
|
AME Elite Consortium Bhd
KLSE:5293
|
$76.60 Million |
|
Rane Holdings Limited
NSE:RANEHOLDIN
|
$76.63 Million |
|
Cantargia AB
ST:CANTA
|
$76.57 Million |
|
Kish Bancorp Inc
OTCQX:KISB
|
$76.56 Million |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
$76.54 Million |
|
ZHOU HEI YA HLDG -000001
F:ZHY
|
$76.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IGM Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 203,234,000 to 48,172,000, a change of -155,062,000 (-76.3%).
- Net loss of 195,795,000 reduced equity.
- Other comprehensive income increased equity by 8,000.
- Other factors increased equity by 40,725,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-195.79 Million | -406.45% |
| Other Comprehensive Income | $8.00K | +0.02% |
| Other Changes | $40.73 Million | +84.54% |
| Total Change | $- | -76.30% |
Book Value vs Market Value Analysis
This analysis compares IGM Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-92.48 | $1.27 | x |
| 2018-12-31 | $-150.27 | $1.27 | x |
| 2019-12-31 | $-11.92 | $1.27 | x |
| 2020-12-31 | $-6.13 | $1.27 | x |
| 2021-12-31 | $-10.57 | $1.27 | x |
| 2022-12-31 | $-13.84 | $1.27 | x |
| 2023-12-31 | $3.89 | $1.27 | x |
| 2024-12-31 | $0.80 | $1.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IGM Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -406.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7308.51%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 5.52x
- Recent ROE (-406.45%) is below the historical average (-65.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.00 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.13 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.82 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.47 Million |
| 2021 | 0.00% | -43901.64% | 0.00x | 0.00x | $-125.31 Million |
| 2022 | 0.00% | -20041.91% | 0.00x | 0.00x | $-156.77 Million |
| 2023 | -121.25% | -11568.83% | 0.01x | 2.08x | $-266.74 Million |
| 2024 | -406.45% | -7308.51% | 0.01x | 5.52x | $-200.61 Million |
Industry Comparison
This section compares IGM Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IGM Biosciences Inc (IGMS) | $100.93 Million | 0.00% | 0.06x | $76.57 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |